SCHEMBL3483301

SCHEMBL3483301

Cc1ccc(S(=O)(=O)OCCCC(=O)OC(C)(C)C)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PSMD10 O75832 1/20 0.41
STAT3 P40763 2/20 0.40
KMT2A Q03164 6/20 0.40
NR1D1 P20393 1/20 0.39
MEN1 O00255 4/20 0.39
ALDH1A1 P00352 3/20 0.39
POLB P06746 1/20 0.38
RAB9A P51151 1/20 0.38
HDAC8 Q9BY41 1/20 0.37
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA9 Q16790 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
MAPT P10636 1/20 0.36
CA2 P00918 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
SIRT5 Q9NXA8 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18530452 0.96 PSMD10 (0.40) PSMD10STAT3KMT2ANR1D1MEN1
SCHEMBL29223514 0.95 HDAC8 (0.41) PSMD10STAT3KMT2ANR1D1MEN1
SCHEMBL22029384 0.95 HDAC8 (0.41) PSMD10STAT3KMT2ANR1D1MEN1
SCHEMBL31682038 0.95 HDAC8 (0.41) PSMD10STAT3KMT2ANR1D1MEN1
SCHEMBL6328499 0.95 HDAC8 (0.41) PSMD10STAT3KMT2ANR1D1MEN1
SCHEMBL7366081 0.92 STAT3 (0.42) PSMD10STAT3KMT2ANR1D1MEN1
SCHEMBL20305525 0.91 HDAC8 (0.39) PSMD10STAT3KMT2ANR1D1MEN1
SCHEMBL28350869 0.91 HDAC8 (0.39) PSMD10STAT3KMT2ANR1D1MEN1
SCHEMBL28950665 0.90 PSMD10 (0.39) PSMD10STAT3KMT2ANR1D1MEN1
SCHEMBL31640131 0.89 STAT3 (0.37) PSMD10STAT3KMT2ANR1D1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117858874-A HPK1 degrading agents, compositions comprising the same, and methods of use thereof 百放开曼有限公司 2024-04-09 CN disclosed
US-7683092-B2 Crystalline forms of antidiabetic compounds MERCK SHARP & DOHME CORP. (US) 2010-03-23 US disclosed
EP-1858844-A4 NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS MERCK & CO INC (US) 2009-04-22 EP disclosed
US-20080221198-A1 Novel Crystalline Forms of Antidiabetic Compounds MERCK SHARP & DOHME CORP. 2008-09-11 US disclosed
EP-1858844-A1 NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS Merck & Co., Inc. (US) 2007-11-28 EP disclosed
WO-2006099077-A1 NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS MERCK & CO., INC. (US) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221198-A1 Novel Crystalline Forms of Antidiabetic Compounds FFAR2, PPARG, PPARA PSMD10 4046/4885STAT3 412/4885KMT2A 1951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.